<DOC>
	<DOCNO>NCT03088176</DOCNO>
	<brief_summary>The purpose study determine safety tolerability combination talimogene laherparepvec combination dabrafenib trametinib BRAF mutate advanced melanoma .</brief_summary>
	<brief_title>Combining Talimogene Laherparepvec With BRAF MEK Inhibitors BRAF Mutated Advanced Melanoma</brief_title>
	<detailed_description>While target therapy successfully block oncogenic signal BRAF mutant melanoma , activation immune response agent talimogene laherparepvec induce durable response subset patient . Combining BRAF inhibitor immunotherapy may specifically target BRAF driver mutation tumor cell potentially sensitize immune system target tumor . The study enroll 20 patient advanced melanoma activate mutation BRAF gene local administration talimogene laherparepvec conjunction oral therapy dabrafenib trametinib , describe safety tolerability combination . Talimogene laherparepvec administer intralesional injection injectable cutaneous , subcutaneous , nodal lesion without image ultrasound guidance . Talimogene laherparepvec administer visceral organ mucosal membrane lesion . The initial dose talimogene laherparepvec 4.0 mL 106 plaque form unit ( PFU ) /mL . Subsequent dos talimogene laherparepvec 4.0 mL 108 PFU/mL . The second dose talimogene laherparepvec ( first dose 108 PFU formulation ) , administer least 21 day follow initial dose . Subsequent dos give approximately every 2 week . Dabrafenib dose 150mg self-administered orally twice per day . Trametinib dose 2mg self-administered orally per day . Subjects evaluate physical exam begin Cycle 1 ( Week 1 ) , Cycle 2 ( Week 4 ) , Cycle 3 ( Week 6 ) , Cycle 4 ( Week 8 ) , every two cycle thereafter . Subjects evaluate dose-limiting toxicity ( define protocol ) Cycle 2 ( Week 4 ) , Cycle 3 ( Week 6 ) , Cycle 4 ( Week 8 ) . Efficacy evaluation perform tumor measurement use clinical assessment , CT PET/CT every 4 cycle first non-baseline measurement prior Cycle 4 . Tumor response evaluate use RECIST 1.1 . Adverse event record grade use Common Terminology Criteria Adverse Events Version 4.0 ( CTCAE v4.0 ) . Other safety assessment include clinical laboratory value physical exam finding . Reporting adverse event , serious adverse event , documentation concomitant medication occur need every cycle . Biopsy melanoma lesion ( preferably uninjected ) occur least one day prior Cycle 4 ( Week 8 ) . Blood biomarker analysis obtain immediately prior on-treatment biopsy , on-treatment biopsy perform , immediately prior Cycle 4 ( Week 8 ) .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>1 . Age ≥ 18 2 . Primary recurrent Stage IIIB IVM1c melanoma surgery recommend 3 . Activating BRAF mutation ( limited V600E V600K mutation treat firstline , include welldefined BRAF mutation failure prior immunotherapy ) 4 . Measurable disease define follow : At least one melanoma lesion accurately serially measure one dimension long diameter ≥10 mm measure caliper , CT scan , MRI . . If lesion lymph node , least one node must able accurately serially measure two dimension , shortaxis must ≥15mm . 5 . Injectable disease ( define least 1cm disease area suitable injection include cutaneous , subcutaneous , nodal lesion ) 1 . Prior therapy talimogene laherparepvec 2 . Prior therapy combination dabrafenib trametinib 3 . Evidence clinically significant immunosuppression follow : 1 . Primary immunodeficiency state Severe Combined Immunodeficiency Disease 2 . Concurrent opportunistic infection 3 . Receiving chronic systemic immunosuppressive therapy ( &gt; 2 week ) , include oral steroid dose &gt; 10mg/day prednisone equivalent except management adverse event CNS metastasis course study . Subjects require intermittent use bronchodilator local steroid injection exclude . 4 . Active herpes infection , herpes require chronic antiherpetic therapy , complication prior herpetic infection ( keratitis encephalitis ) 5 . Chronic use immunosuppressant steroid ( define prednisone 10mg/day equivalent ) 6 . Clinically active cerebral metastasis 7 . History evidence melanoma associate immunodeficiency state 8 . History malignancy within prior 24 month exception breast bladder carcinoma situ , nonmelanomatous skin cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>BRAF inhibitor</keyword>
	<keyword>Intratumoral injection</keyword>
	<keyword>Talimogene laherparepvec</keyword>
	<keyword>MEK inhibitor</keyword>
	<keyword>dabrafenib</keyword>
	<keyword>trametinib</keyword>
</DOC>